Biochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia

Critical Reviews in Clinical Laboratory Sciences

Volumn 37, Issue 5, 2000, Pages 431-502

  Fosslien, E ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

Author keywords

Carcinogenesis; COX 1; COX 2; Cyclooxygenase; NSAIDs; Prostaglandin

Indexed keywords

4 [5 (4 CHLOROPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; 5 (4 FLUOROPHENYL) 1 [(4 METHYLSULFONYL)PHENYL] 3 TRIFLUOROMETHYLPYRAZOLE; 6 (2,4 DIFLUOROPHENYLTHIO) 5 METHANESULFONAMIDO 1 INDANONE; ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; FLOSULIDE; FLURBIPROFEN; INDOMETACIN; MELOXICAM; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NAPROXEN; NIMESULIDE; NIMID; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; ROFECOXIB; STEROID; SULINDAC; TILMACOXIB; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; CANCER; CANCER PREVENTION; CANCER THERAPY; DIGESTIVE SYSTEM ULCER; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; DRUG SELECTIVITY; HUMAN; HUMAN CELL; KIDNEY INJURY; NONHUMAN; PRIORITY JOURNAL; REVIEW; THROMBOCYTE DYSFUNCTION;

ANIMALIA;

EID: 0034471496     PISSN: 10408363     EISSN: None     Source Type: Journal    
DOI: 10.1080/10408360091174286     Document Type: Review

References (333)

1. COX-2 in large bowel cancer: A one-sided story
2. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs
3. Mechanism of action of aspirin-like drugs
4. On the mechanism of the biosynthesis of prostaglandins E-1 and F-1-alpha
5. Adverse effects of nonsteroidal antiinflammatory drugs on the gastrointestinal system
6. Molecular pathology of cyclooxygenase-2 in neoplasia
7. Cyclooxygenase regulates angiogenesis induced by colon cancer cells
8. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential
9. Dominance of cyclooxygenase-2 in the regulation of pancreatic islet prostaglandin synthesis
10. Non-steroidal antiinflammatory drugs and cyclooxygenase-2 selectivity in gastroenterology
11. Cytochrome P450 and arachidonic acid bioactivation. Molecular and functional properties of the arachidonate monooxygenase
12. Mechanism for irreversible self-deactivation of prostaglandin synthetase
13. Role of interleukin 1 in the regulation of cyclooxygenase gene expression in rat endometrial stromal cells
14. Selective inhibition of cyclooxygenase 2
15. Arachidonic acid oxygenation by COX-1 and COX-2. Mechanisms of catalysis and inhibition
16. Cyclooxygenase knockout mice: Models for elucidating isoform-specific functions
17. Multiple roles of inducible cyclooxygenase-2 and its selective inhibitors
18. Human cyclooxygenase-2 cDNA
19. Cyclooxygenases 1 and 2
20. Primary structure of prostaglandin G/H synthase from sheep vesicular gland determined from the complementary DNA sequence
21. Primary structure of sheep prostaglandin endoperoxide synthase deduced from cDNA sequence
22. Isolation and characterization of the complementary DNA for sheep seminal vesicle prostaglandin endoperoxide synthase (cyclooxygenase)
23. Identification of a phorbol ester-repressible v-src-inducible gene
24. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing
25. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue
26. A serum- and glucocorticoid-regulated 4-kilobase mRNA encodes a cyclooxygenase-related protein
27. Cyclooxygenase-1 and -2 isoenzymes
28. Expression of cyclooxygenase-2 in rat vascular smooth muscle cells is unrelated to nuclear factor-kappaB activation
29. Transcriptional regulation of cyclooxygenase-2 in mouse skin carcinoma cells. Regulatory role of CCAAT/enhancer-binding proteins in the differential expression of cyclooxygenase-2 in normal and neoplastic tissues
30. Involvement of NF-kappaB in silica-induced cyclooxygenase II gene expression in rat alveolar macrophages
31. Structure of the human cyclo-oxygenase-2 gene
32. Molecular characterization of the 5.2 KB isoform of the human cyclooxygenase-1 transcript
33. Cytokine induction of nuclear factor kappa B in cycling and growth-arrested cells. Evidence for cell cycle-independent activation
34. Inducibility of kappa immunoglobulin enhancer-binding protein Nfkappa B by a posttranslational mechanism
35. Achieving transcriptional specificity with NF-kappa B
36. Hypoxia induces high-mobility-group protein I(Y) and transcription of the cyclooxygenase-2 gene in human vascular endothelium
37. Involvement of NF-kappaB in the regulation of cyclooxygenase-2 protein expression in LPS-stimulated J774 macrophages
38. Inducibility of E4BP4 suggests a novel mechanism of negative gene regulation by glucocorticoids
39. Regulation of cyclooxygenase-2 expression in bovine chondrocytes in culture by interleukin 1alpha, tumor necrosis factor-alpha, glucocorticoids, and 17beta-estradiol
40. Induction of cyclooxygenase-2 by interleukin-1 alpha. Evidence for post-transcriptional regulation
41. Interleukin-1 beta induces cyclooxygenase-2 gene expression in cultured endometrial stromal cells
42. Involvement of nuclear factor kappa B in the regulation of cyclooxygenase-2 expression by interleukin-1 in rheumatoid synoviocytes
43. Hypoxia induces cyclooxygenase-2 via the NF-kappaB p65 transcription factor in human vascular endothelial cells
44. Up-regulation of cyclooxygenase-2 gene expression by chorionic gonadotropin in mucosal cells from human fallopian tubes
45. Role of centrally administered melatonin and inhibitors of COX and NOS in LPS-induced hyperthermia and adipsia
46. Purification of prostaglandin endoperoxide synthetase from bovine vesicular gland microsomes
47. The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1
48. Structural basis for selective inhibition of cyclooxygenase-2 by antiinflammatory agents
49. The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase
50. Prostaglandin endoperoxide synthase: Why two isoforms?
51. Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues
52. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2
53. Nonsteroidal antiinflammatory drugs cause apoptosis and induce cyclooxygenases in chicken embryo fibroblasts
54. Cyclooxygenase-2 unlike cyclooxygenase-1 is highly expressed in ovine embryos during the implantation period
55. Controlling the production of interleukin-1 and tumor necrosis factor in disease
56. Localization of cyclooxygenase-2 and regulation of its mRNA expression in gastric ulcers in rats
57. Evidence for involvement of NF-kappaB in the transcriptional control of COX-2 gene expression by IL-1beta
58. Alternate COX-2 transcripts are differentially regulated: Implications for post-transcriptional control
59. Tumor necrosis factor-alpha promotes sustained cyclooxygenase-2 expression: Attenuation by dexamethasone and NSAIDs
60. Enhanced cyclooxygenase-2 gene expression in alcoholic liver disease in the rat
61. Prostaglandin E2 and other cyclic AMP-elevating agents modulate IL-2 and IL-2R alpha gene expression at multiple levels
62. Prostaglandin E2 differentially modulates cytokine secretion profiles of human T helper lymphocytes
63. Serial analysis of gene expression in human monocytes and macrophages
64. Endotoxin signal transduction in macrophages
65. Different intracellular locations for prostaglandin endoperoxide H synthase-1 and -2
66. The mouse macrophage activation-associated marker protein, p71/73, is an inducible prostaglandin endoperoxidase synthase (cyclooxygenase)
67. Aberrant prostaglandin synthase 2 expression defines an antigen-presenting cell defect for insulin-dependent diabetes mellitus
68. Inhibition of cyclooxygenase-2 rapidly reverses inflammatory hyperalgesia and prostaglandin E2 production
69. The role of cyclooxygenases in inflammation, cancer, and development
70. Cyclooxygenase, NSAIDs, and colorectal cancer
71. Chemoprevention of colorectal cancer: Dietary and pharmacologic approaches
72. Colon cancer prevention by NSAIDs: What is the mechanism of action?
73. The role of COX-2 in intestinal cancer
74. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas
75. Expression of cyclooxygenase-1 and -2 in human colorectal cancer
76. Colorectal cancer and nonsteroidal antiinflammatory drugs
77. Size- and invasion-dependent increase in cyclooxygenase 2 levels in human colorectal carcinomas
78. Sulindac and polyp regression
79. Mutation and cancer in man
80. Increased expression of cyclooxygenase-2 to -1 in human colorectal cancers and adenomas, but not in hyperplastic polyps
81. Suppression of intestinal polyposis in Apc delta 716 knockout mice by inhibition of cyclooxygenase 2 (COX-2)
82. Early expression of cyclo-oxygenase-2 during sporadic colorectal carcinogenesis
83. The relationship between cyclooxygenase-2 expression and colorectal cancer
84. Differential expression of cyclooxygenase 2 in human colorectal cancer
85. Cyclooxygenase (COX)-2 immunoreactivity and relationship to p53 and Ki-67 expression colorectal cancer
86. Prostaglandin levels in human colorectal mucosa: Effects of sulindac in patients with familial adenomatous polyposis
87. Heterogeneous distribution of COX-2 over-expression in human colon carcinoma cells
88. Induction of an acetaminophen-sensitive cyclooxygenase with reduced sensitivity to nonsteroid antiinflammatory drugs
89. Differential expression and regulation of cyclooxygenase-1 and -2 in two human breast cancer cell lines
90. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer
91. Estrogen upregulates cyclooxygenase-1 gene expression in ovine fetal pulmonary artery endothelium
92. Developmental expression of the cyclo-oxygenase-1 and cyclo-oxygenase-2 genes in the peri-implantation mouse uterus and their differential regulation by the blastocyst and ovarian steroids
93. Expression of cyclooxygenase-2 in human lung carcinoma
94. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas
95. Expression of cyclooxygenase-2 in human hepatocellular carcinoma: Relevance to tumor dedifferentiation
96. Cyclooxygenase-2 expression in hepatocellular carcinoma
97. COX-2 expression is induced by UVB exposure in human skin: Implications for the development of skin cancer
98. Expression of cyclooxygenase-2 protein in gastric adenocarcinoma
99. Cyclooxygenase-2 overexpression enhances lymphatic invasion and metastasis in human gastric carcinoma
100. Cyclooxygenase-2 expression in human esophageal carcinoma
101. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer
102. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck
103. Overexpression of cyclooxygenase-2 in human prostate adenocarcinoma
104. Repression of cyclooxygenase-2 and prostaglandin E2 release by dexamethasone occurs by transcriptional and post-transcriptional mechanisms involving loss of polyadenylated mRNA
105. Role and regulation of cyclooxygenase-2 during inflammation
106. Nonsteroidal antiinflammatory drugs: Practical and theoretical considerations in their selection
107. The effect of aspirin and nonsteroidal antiinflammatory drugs on prostaglandins
108. Kinetic basis for selective inhibition of cyclooxygenases
109. The structural and electronical factors that contribute affinity for the time-dependent inhibition of PGHS-1 by indomethacin, diclofenac and fenamates
110. Sites of action for future therapy: An adenosine-dependent mechanism by which aspirin retains its antiinflammatory activity in cyclooxygenase-2 and NFkappaB knockout mice
111. Plasma and rectal adenosine in inflammatory bowel disease: Effect of methotrexate
112. Regulation of nitric oxide and prostaglandin E2 production by CSAIDS (SB203580) in murine macrophages and bovine chondrocytes stimulated with LPS
113. Use of nonsteroidal antiinflammatory drugs and incidence of colorectal cancer: A population-based study
114. Rheumatoid arthritis and the risk of malignancy
115. Aspirin use and colorectal cancer: Post-trial follow-up data from the Physicians' Health Study
116. Low-dose aspirin and incidence of colorectal tumors in a randomized trial
117. Association between coronary heart disease and cancer of the breast, prostate, and colon
118. Over-the-counter analgesics and risk of ovarian cancer
119. Nonsteroidal antiinflammatory drugs and breast cancer
120. Prospective study of nonsteroidal antiinflammatory drugs and breast cancer
121. The effects of NSAIDs on breast cancer prognostic factors
122. Aspirin and gastrointestinal cancer
123. Aspirin, non-steroidal antiinflammatory drugs and protection from colorectal cancer: A review of epidemiological evidence
124. Non-small cell lung cancer cycloxygenase activity and proliferation are inhibited by non-steroidal antiinflammatory drugs
125. Apoptosis induced by NS-398, a selective cyclooxygenase-2 inhibitor, in human colorectal cancer cell lines
126. Suppression of inducible cyclooxygenase 2 gene transcription by aspirin and sodium salicylate
127. Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis
128. Effects of nonsteroidal antiinflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway
129. Sulindac sulfide inhibits the proliferation of colon cancer cells: Diminished expression of the proliferation markers PCNA and Ki-67
130. Sulindac sulfide alters the expression of cyclin proteins in HT-29 colon adenocarcinoma cells
131. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal antiinflammatory drugs
132. Up-regulation of cyclooxygenase-2 by product-prostaglandin E2
133. Early pathogenic events in NSAID-induced gastrointestinal damage
134. Nonsteroidal antiinflammatory drugs and uncoupling of mitochondrial oxidative phosphorylation
135. Diphenylamine as an important structure of nonsteroidal antiinflammatory drugs to uncouple mitochondrial oxidative phosphorylation
136. Primary changes in liver damage by aspirin in rats
137. Inhibition and uncoupling of oxidative phosphorylation by nonsteroidal antiinflammatory drugs: Study in mitochondria, submitochondrial particles, cells, and whole heart
138. Indomethacin suppresses the growth of colon 26, Meth-A and FM3A tumors in mice by reducing the prostaglandin E2 content and telomerase activity in tumor tissues
139. Mitochondrial damage: A possible mechanism of the "topical" phase of NSAID induced injury to the rat intestine
140. Comparison of indomethacin and nimesulide, a selective cyclooxygenase-2 inhibitor, on key pathophysiologic steps in the pathogenesis of nonsteroidal antiinflammatory drug enteropathy in the rat
141. Cyclooxygenase-2-selective antagonists do not inhibit growth of colorectal carcinoma cell lines
142. Blockade of long chain fatty acid oxidation by non-steroidal antiinflammatory drugs may contribute to inhibition of proliferation of human colorectal carcinoma cell lines
143. Binding of nonsteroidal antiinflammatory drugs to the alpha-subunit of the trifunctional protein of long chain fatty acid oxidation
144. Nonsteroidal antiinflammatory drugs enhance glutathione S-transferase theta levels in rat colon
145. Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats
146. Chemoprevention of intestinal adenomas in the APCMin mouse by piroxicam: Kinetics, strain effects and resistance to chemosuppression
147. Nonsteroidal antiinflammatory drugs, eicosanoids, and colorectal cancer prevention
148. Genotype-phenotype correlation in murine APC mutation: Differences in enterocyte migration and response to sulindac
149. Inhibition of angiogenesis by sulindac and its sulfone metabolite (FGN-1): A potential mechanism for their antineoplastic properties
150. Aberrant crypt foci of the colon as precursors of adenoma and cancer
151. G1 delay in cells overexpressing prostaglandin endoperoxide synthase-2
152. Clinical and genomic influence of sulindac on rectal mucosa in familial adenomatous polyposis
153. Gastrointestinal effects of nonsteroidal antiinflammatory therapy
154. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysis
155. Defining patients at risk of non-steroidal antiinflammatory drug gastropathy
156. Adverse effects of low-dose aspirin in a healthy elderly population
157. An endoscopic study of gastroduodenal lesions induced by nonsteroidal antiinflammatory drugs
158. Nephrotoxicity of nonsteroidal antiinflammatory drugs: Physiologic foundations and clinical implications
159. Effects of nonsteroidal antiinflammatory drugs on platelet function and systemic hemostasis
160. Effects of nonsteroidal antiinflammatory therapy on platelets
161. Retrospective study of adverse reactions to non steroid antiinflammatory drugs (NSAIDs): Predictive value of controlled challenge with alternative drugs
162. The classification of cyclooxygenase inhibitors
163. Preferential COX-2 inhibition: Its clinical relevance for gastrointestinal nonsteroidal antiinflammatory rheumatic drag toxicity
164. Experiemental models used to investigate the differential inhibition of cyclooxygenases-1 and cyclooxygenase-2 by non-steroidal antiinflammatory drugs
165. Effect of antiinflammatory drugs on COX-1 and COX-2 activity in human articular chondrocytes
166. Development of an in-vitro test system for the evaluation of cyclooxygenase-2 inhibitors
167. Rofecoxib [Vioxx, MK-0966;4-(4′-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: A potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles
168. Ex vivo assay to determine the cyclooxygenase selectivity of nonsteroidal antiinflammatory drugs
169. Differential allosteric regulation of prostaglandin H synthase 1 and 2 by arachidonic acid
170. Inhibition of prostaglandin synthesis up-regulates cyclooxygenase-2 induced by lipopolysaccharide and peroxisomal proliferators
171. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: Identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-y1]benze nesulfonamide(SC-58635, celecoxib)
172. COX 2-selective NSAIDs: Biology, promises, and concerns
173. Cyclooxygenase-2 specificity and its clinical implications
174. Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: What can we expect?
175. Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: A randomized, controlled trial
176. Wound collagen deposition in rats: Effects of an NO-NSAID and a selective COX-2 inhibitor
177. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis
178. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis
179. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis
180. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: Efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects
181. The cyclooxygenase-2 inhibitors: Safety and effectiveness
182. Effect of structural modification of enol-carboxamide-type nonsteroidal antiinflammatory drugs on COX-2/COX-1 selectivity
183. Effects of meloxicam and indomethacin on cyclooxygenase pathways in healthy volunteers
184. Meloxicam inhibits the growth of colorectal cancer cells
185. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2
186. Modulation of oxidant status by meloxicam in experimentally induced arthritis
187. Future trends in the development of safer nonsteroidal antiinflammatory drugs
188. Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model
189. Selective inhibitors of COX-2
190. Evidences for involvement of cyclooxygenase-2 in proliferation of two gastrointestinal cancer cell lines
191. Effects of NSAIDs on proliferation of gastric cancer cells in vitro: Possible implication of cyclooxygenase-2 in cancer development
192. Inhibitory effect of NS-398, a selective cyclooxygenase-2 inhibitor, on azoxymetane-induced aberrant crypt foci in colon carcinogenesis of F344 rats
193. NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bc1-2 expression in LNCaP cells
194. Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal antiinflammatory drug: Independence from COX-2 protein expression
195. A comparative study of the effect of ten non-steroid antiinflammatory drugs (NSAIDS) upon some mitochondrial and platelet functions
196. Prostaglandin E(2) mediates inhibition of insulin secretion by interleukin-1beta
197. Aspirin, but not sodium salicylate, indomethacin, or nabumetone, reversibly suppresses 1,2-dimethylhydrazine-induced colonic aberrant crypt foci in rats
198. Inhibitory effects of nabumetone, a cyclooxygenase-2 inhibitor, and esculetin, a lipoxygenase inhibitor, on N-methyl-N-nitrosourea-induced mammary carcinogenesis in rats
199. Role of arachidonic acid metabolites in tumor growth inhibition by nonsteroidal antiinflammatory drugs
200. Safety profiles of leading nonsteroidal antiinflammatory drugs
201. The gastroduodenal effects of buffered aspirin, carprofen, and etodolac in healthy dogs
202. Pharmacokinetic and pharmacodynamic action of etodolac in patients after oral surgery
203. A single amino acid difference between cyclooxygenase-1 (COX-1) and -2 (COX-2) reverses the selectivity of COX-2 specific inhibitors
204. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain
205. The effect of selective cyclooxygenase inhibitors on intestinal epithelial cell mitogenesis
206. Molecular model of the interaction between nimesulide and human cyclooxygenase-2
207. Structural basis for selective inhibition of COX-2 by nimesulide
208. The in vivo assessment of nimesulide cyclooxygenase-2 selectivity
209. Effects of the nonsteroidal antiinflammatory drug nimesulide on energy metabolism in livers from adjuvant-induced arthritic rats
210. Suppressive effects of nimesulide, a selective inhibitor of cyclooxygenase-2, on azoxymethane-induced colon carcinogenesis in mice
211. Profile of JTE-522 as a human cyclooxygenase-2 inhibitor
212. Inhibition of haematogenous metastasis of colon cancer in mice by a selective COX-2 inhibitor, JTE-522
213. Structure-based design of COX-2 selectivity into flurbiprofen
214. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids
215. Abnormalities of chromosome No. 1 in human solid malignant tumours
216. Abnormalities of chromosome No. 1: Significance in malignant transformation
217. Cyclooxygenase-2 expression in human adenocarcinoma cell line HT29 cl.19A
218. The inducible prostaglandin biosynthetic enzyme, cyclooxygenase 2, is not mutated in patients with attenuated adenomatous polyposis coli
219. Growth stimulation and induction of epidermal growth factor receptor by overexpression of cyclooxygenases 1 and 2 in human colon carcinoma cells
220. E-cadherin downregulation in cancer: Fuel on the fire?
221. Tumorigenic transformation of immortalized ECV endothelial cells by cyclooxygenase-1 overexpression
222. Growth stimulation and induction of epidermal growth factor receptor by overexpression of cyclooxygenases 1 and 2 in human colon carcinoma cells
223. Localization of 5-lipoxygenase to the nucleus of unstimulated rat basophilic leukemia cells
224. Rapid import of cytosolic 5-lipoxygenase into the nucleus of neutrophils after in vivo recruitment and in vitro adherence
225. Cell biology of the 5-lipoxygenase pathway
226. Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse
227. Biologic effects of nonsteroidal antiinflammatory drugs
228. Compensatory prostaglandin E2 biosynthesis in cyclooxygenase 1 or 2 null cells
229. Induction of an acetaminophen-sensitive cyclooxygenase with reduced sensitivity to nonsteroid antiinflammatory drugs
230. Specific COX-2 inhibitors in arthritis, oncology, and beyond: Where is the science headed?
231. Multiple female reproductive failures in cyclooxygenase 2-deficient mice
232. Anovulation in cyclooxygenase-2-deficient mice is restored by prostaglandin E and interleukin-1beta
233. Cyclo-oxygenase-2-derived prostacyclin mediates embryo implantation in the mouse via PPARdelta
234. Up-regulation of cyclooxygenase-2 gene expression by chorionic gonadotropin during the differentiation of human endometrial stromal cells into decidua
235. Constitutive expression of cyclooxygenase-2 in rat vas deferens
236. Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration
237. NSAID treatment of gastrointestinal abnormalities: A challenge to 'cytoprotection'
238. Beneficial effects of NSAIDs in the gastrointestinal tract
239. COX-2 compensation in the uterus of COX-1 deficient mice during the preimplantation period
240. Resistance to apoptosis and cyclooxygenase-2 expression in a human adenocarcinoma cell line HT29 CL.19A
241. Cyclooxygenase-2 gene expression is upregulated in transformed mammary epithelial cells
242. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells
243. Sulindac derivatives inhibit growth and induce apoptosis in human prostate cancer cell lines
244. Induction of cyclooxygenase (COX)-2 but not COX-1 gene expression in apoptotic cell death
245. Specific NF-kappaB blockade selectively inhibits tumour necrosis factor-alpha-induced COX-2 but not constitutive COX-1 gene expression in HT-29 cells
246. COX-2 inhibitors. A new class of antiangiogenic agents
247. Thromboxane A2 is a mediator of cyclooxygenase-2-dependent endothelial migration and angiogenesis
248. Significant roles of inducible cyclooxygenase (COX)-2 in angiogenesis in rat sponge implants
249. Subversion of immune system by tumor cells and role of prostaglandin
250. Subversive activity of syngeneic tumor cells as an escape mechanism from immune suverillance and the role of prostaglandins
251. Tumor-mediated immunosuppression: Prevention by inhibitors of prostaglandin synthesis
252. Production of prostaglandin E2 by tumor cells in vitro
253. Enhancement in immunity of tumor bearing mice by immunization against prostaglandin E2
254. Enhancement of immune function and tumor growth inhibition by antibodies against prostaglandin E2
255. Immunosubversive role of PGE2 in tumor bearing mice
256. Amplification by macrophages of prostaglandin-mediated immunosuppression in mice bearing syngeneic tumors
257. Prostaglandin E production by Lewis lung carcinoma: Mechanism for tumor establishment in vivo
258. Prostaglandin production in mouse mammary tumour cells confers invasive growth potential by inducing hepatocyte growth factor in stromal fibroblasts
259. Prostaglandin E2 production by EL 4 leukemia cells from C57B/6 mice: Mechanism for tumor dissemination
260. Enhancement of Lewis lung carcinoma cell migration by prostaglandin E2 produced by macrophages
261. Association of increased tumor cell responsiveness to prostaglandin E2 with more aggressive tumor behavior
262. Maize meal, non-esterified linoleic acid, and endemic cancer of the esophagus - Preliminary findings
263. Modulation of macrophage and B cell function by glycosaminoglycans
264. Transcriptional regulation of cyclooxygenase-2 in mouse skin carcinoma cells. Regulatory role of CCAAT/enhancer-binding proteins in the differential expression of cyclooxygenase-2 in normal and neoplastic tissues
265. Induction of cyclooxygenase-2 mRNA by prostaglandin E2 in human prostate carcinoma cells
266. Regulation of cyclooxygenase gene expression in rat endometrial stromal cells: The role of epidermal growth factor
267. Rapid and transient induction of cyclo-oxygenase 2 by epidermal growth factor in human amnion-derived WISH cells
268. Retinoids suppress epidermal growth factor-induced transcription of cyclooxygenase-2 in human oral squamous carcinoma cells
269. Enhancement of prostaglandin E2 production by epidermal growth factor requires the coordinate activation of cytosolic phospholipase A2 and cyclooxygenase 2 in human squamous carcinoma A431 cells
270. Stimulation of prostaglandin production by hepatocyte growth factor in human gastric carcinoma cells
271. Epidermal-growth-factor-receptor expression is associated with rapid tumor proliferation in bladder cancer
272. Level and function of epidermal growth factor receptor predict the metastatic potential of human colon carcinoma cells
273. Benign and malignant smooth muscle tumors containing Epstein-Barr virus in children with AIDS
274. Adrenal gland leiomyoma in a child with acquired immunodeficiency syndrome
275. A newly recognized cause of wheezing: AIDS-related broncial leiomyomas
276. Unusual dural and skull-based mesenchymal neoplasms: A report of four cases
277. Detection of Epstein Barr virus in an leiomyomatous neoplasm in an adult immunodeficiency virus 1-infected patient
278. Epstein-Barr virus-associated hepatic smooth muscle neoplasm in a cardiac transplant patient
279. A second Epstein-Barr virus membrane protein (LMP2) is expressed in latent infection and colocalizes with LMP1
280. Biochemical and genetic studies of Epstein-Barr virus latent membrane protein 2
281. Two related Epstein-Barr virus membrane proteins are encoded by separate genes
282. The Epstein-Barr virus latent membrane protein 1 induces expression of the epidermal growth factor receptor
283. Control of cell cycle entry and apoptosis in B lymphocytes infected by Epstein-Barr virus
284. Precise mapping of the EGF receptor gene on the human chromosome 7p12 using an improved fish technique
285. Analysis of the transcriptional activity of amplified genes in tumour cells by fluorescence in situ hybridization
286. Mega base map of the epidermal growth factor (EGF) receptor gene flanking regions and structure of the amplification units in EGF receptor-hyperproducing squamous carcinoma cells
287. Inhibition of human colon cancer malignant cell behavior and growth by antisense epidermal growth factor receptor expression vector
288. Cyclooxygenase-2 alters transforming growth factor-beta 1 response during intestinal tumorigenesis
289. TGF-beta1 in colonic neoplasia: A genetic molecular and immunohistochemical study
290. Coordinate regulation of cyclooxygenase-2 and TGFbeta1 in replication error-positive colon cancer and azoxymethane-induced rat colonic tumors
291. TGF-beta expression in the human colon: Differential immunostaining along crypt epithelium
292. High levels of transforming growth factor beta 1 correlate with disease progression in human colon cancer
293. Chemoprevention of colonic aberrant crypt foci by an inducible nitric oxide synthase-selective inhibitor
294. Dihydroxy bile acids activate the transcription of cyclooxygenase-2
295. Curcumin inhibits cyclooxygenase-2 transcription in bile acid- and phorbol ester-treated human gastrointestinal epithelial cells
296. Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis
297. Prostaglandin J2 and 15-deoxy-delta12,14-prostaglandin J2 induce proliferation of cyclooxygenase-depleted colorectal cancer cells
298. Matrilysin in early stage intestinal tumorigenesis
299. Differential expression of matrilysin and cyclooxygenase-2 in intestinal and colorectal neoplasms
300. Benzo[a]pyrene up-regulates cyclooxygenase-2 gene expression in oral epithelial cells
301. Antioxidants reduce cyclooxygenase-2 expression, prostaglandin production, and proliferation in colorectal cancer cells
302. Epidermal growth factor receptor activation induces nuclear targeting of cyclooxygenase-2, basolateral release of prostaglandins, and mitogenesis in polarizing colon cancer cells
303. Antioxidants inhibit interleukin-1-induced cyclooxygenase and nitric-oxide synthase expression in rat mesangial cells. Evidence for post-transcriptional regulation
304. Expression of 15-lipoxygenase-1 in human colorectal cancer
305. Risk of Alzheimer's disease and duration of NSAID use
306. Importance of immunological and inflammatory processes in the pathogenesis and therapy of Alzheimer's disease
307. Use of aspirin in coronary disease
308. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
309. Agumented expression of cyclooxygenase-2 in human atherosclerotic lesions
310. When to try COX-2-specific inhibitors. Safer than standard NSAIDs in some situations
311. Specific cyclooxygenase-2 (COX-2) inhibitors
312. Chemoprevention of colorectal cancer through inhibition of cyclooxygenase-2
313. Nonsteroidal antiinflammatory drug use and protection against colorectal cancer in women
314. Not a mouse stirring: Deletion of the EP2 and love's labor's lost
315. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II
316. Reduced fertility and postischaemic brain injury in mice deficient in cytosolic phospholipase A2
317. Identification of specific EP receptors responsible for the hemodynamic effects of PGE2
318. International Union of Pharmacology classification of prostanoid receptors: Properties, distribution, and structure of the receptors and their subtypes
319. Salt-sensitive hypertension and reduced fertility in mice lacking the prostaglandin EP2 receptor
320. Reproductive failure and reduced blood pressure in mice lacking the EP2 prostaglandin E2 receptor
321. Impaired febrile response in mice lacking the prostaglandin E receptor subtype EP3
322. The prostaglandin receptor EP4 triggers remodelling of the cardiovascular system at birth
323. Altered pain perception and inflammatory response in mice lacking prostacyclin receptor
324. Female reproduction in mice lacking the prostaglandin F receptor. Roles of prostaglandin and oxytocin receptors in parturition
325. Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal antiinflammatory agent
326. Inhibition of lung tumorigenesis by NSAIDS: A working hypothesis
327. Effects of NSAIDs on NNK-induced pulmonary and gastric tumorigenesis in A/J mice
328. Clinical experience with cyclooxygenase-2 inhibitors
329. COX-2 and colon cancer
330. Cyclooxygenase selectivity and the risk of gastro-intestinal complications of various non-steroidal antiinflammatory drugs: A clinical consideration
331. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor
332. Chemopreventive effect of N-(2-cyclohexyloxy-4-nitrophenyl)methane sulfonamide (NS-398), a selective cyclooxygenase-2 inhibitor, in rat colon carcinogenesis induced by azoxymethane